Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Investor Presentation (May 2024)
24 slides from Arbutus Biopharma's investor presentation, May 2, 2024
Slide 1: Corporate Presentation
NASDAQ: ABUS www.arbutusbio.com May 2, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc.
Slide 2: Forward-Looking Statements
Forward - Looking Statements © 2024 Arbutus Biopharma, Inc. 2 This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified a
Slide 3: Our Strategy for Value Creation
Our Strategy for Value Creation Leverage the proven track record of success established with our team's expertise in understanding and treating viral infections by discovering and developing a differentiated pipeline of therapies targeting chronic HBV. Develop a combination therapy that includes ant
Slide 4: Investment Highlights
Investment Highlights Strong financial position Indications with significant unmet medical need & large market opportunities Patented LNP technology Portfolio of internally discovered assets with distinct MOAs Lead HBV compound – imdusiran (AB - 729) RNAi therapeutic in multiple Phase 2a combination
Slide 5: Pipeline
Pipeline AB - 101 cHBV Imdusiran (AB - 729) cHBV RNAi Therapeutic PD - L1 Inhibitor AB - 101 - 001 single - /multiple - ascending dose Pre - Clinical Phase 1 Phase 2 Phase 3 Marketed AB - 729 - 201 Combo trial (imdusiran + Peg - IFNα - 2a + NA) AB - 729 - 202 Combo trial (imdusiran + vaccine + NA +/
Slide 6: HBV Overview
HBV Overview Cause & Symptoms Life - threatening liver infection caused by hepatitis B virus (HBV) Transmitted through body fluids and from mother to child Long - term chronic infection (cHBV) leads to higher risk of cirrhosis and/or liver cancer Diagnosis HBsAg detection Additional biomarkers neces
Slide 7: HBV Presents a Significant Unmet Medical Need
Africa 60M SE Asia 39M W Pacific 115M EU 15M E Mediterranean 21M Americas 7M ~820k people die every year as a consequence despite the availability of effective vaccines and antivirals. >290M people are chronically infected with HBV, globally. >290M Chronic HBV Sources: https://www.who.int/news - roo
Slide 8: Pronged Approach to Therapeutic Success Leading to an HBV Cure
Suppress Reduce Boost Leading to an HBV Cure 3 - Pronged Approach to Therapeutic Success Therapeutic success will require a combination of agents with complementary MOAs. Suppress HBV DNA Reduce viral antigens Boost host immune response Viral DNA and cccDNA Pool NA RNAi Viral Antigen - HBsAg RNAi Ho
Slide 9: RNAi Therapeutic
RNAi Therapeutic 9 © 2024 Arbutus Biopharma, Inc.
Slide 10: Imdusiran RNAi Therapeutic
Single trigger RNAi agent targeting all HBV transcripts Inhibits HBV replication and lowers all HBV antigens Pan - genotypic activity across HBV genotypes Demonstrated complementarity with other agents Actively targets the liver Active against cccDNA derived and integrated HBsAg transcripts Clean pr
Slide 11: Phase 1a/1b Clinical Trial: Key Takeaways
AB - 729 - 001 Phase 1a/1b Clinical Trial : Key Takeaways Imdusiran provided robust and comparable HBsAg declines regardless of dose, dosing interval, HBeAg or DNA status A reduction in HBsAg and HBV DNA was sustained in the majority of patients that stopped all treatments Imdusiran was generally sa
Slide 12: 201: Phase 2a POC Clinical Trial
AB - 729 - 201: Phase 2a POC Clinical Trial Imdusiran in combination with ongoing NA therapy and short courses of Peg - IFNα - 2a in cHBV patients Follow - up (24 - weeks) A1: Imdusiran + NA + IFN (n=12) A2: NA + IFN (n=13) B1: Imdusiran + NA + IFN (n=8) B2: NA + IFN (n=10) Imdusiran + NA (60mg Q8W)
Slide 13: 201: Individual and Mean HBsAg Results by Cohort Over Time
Individual and Mean HBsAg Results by Cohort Over Time © 2024 Arbutus Biopharma, Inc. 13 AB - 729 - 201: Imdusiran Treatment Led to Consistent HBsAg Declines; IFN may contribute to additional declines Mean (SE) HBsAg log 10 Change from Baseline at Key Timepoints Data presented at EASL 2023 Preliminar
Slide 14: 202: Phase 2a POC Clinical Trial
POC Phase 2a clinical trial evaluating imdusiran in combination with Barinthus Bio’s immunotherapeutic, VTP - 300, NA and with or without low dose nivolumab AB - 729 - 202: Phase 2a POC Clinical Trial Primary objective: evaluate safety and reactogenicity of imdusiran followed by VTP - 300 or placebo
Slide 15: 202: HBsAg Levels Reduced and Sustained with Imdusiran and VTP-300
AB - 729 - 202: HBsAg Levels were Reduced and Sustained with Imdusiran and VTP - 300 Treatment Mean HBsAg Change from Baseline and Key Milestones Data presented at AASLD 2023 © 2024 Arbutus Biopharma, Inc. 15 Mean HBsAg Change from Baseline by Treatment Group Preliminary results: Robust reductions o
Slide 16: 203: Phase 2a POC Clinical Trial
AB - 729 - 203: Phase 2a POC Clinical Trial Imdusiran in combination with NA therapy and intermittent low doses of durvalumab, an anti - PD - L1 monoclonal antibody Primary objective : evaluate safety, tolerability and antiviral activity of imdusiran and NA therapy in combination with durvalumab N=3
Slide 17: Imdusiran Strategic Collaboration
Imdusiran Strategic Collaboration Exclusive Licensing* and Strategic Partnership Develop, manufacture and commercialize imdusiran in mainland China, Hong Kong, Macau and Taiwan *ABUS retains the non - exclusive right to develop and manufacture in the Qilu territory for exploiting AB - 729 in the res
Slide 18: Oral PD-L1 Inhibitor
Oral PD - L1 Inhibitor 18 © 2024 Arbutus Biopharma, Inc.
Slide 19: AB-101: Oral PD-L1 Inhibitor for HBV Immune Reactivation
AB - 101: Oral PD - L1 Inhibitor for HBV Immune Reactivation Currently in a Phase 1a/1b clinical trial Rationale • HBV immune tolerance is a critical driver of cHBV infection • PD - 1:PD - L1 checkpoint axis plays a key role in immune tolerization in cHBV • PD - L1 expression upregulated during HBV
Slide 20: AB-101: Small-Molecule Oral PD-L1 Inhibitor for HBV
AB - 101: Small - Molecule Oral PD - L1 Inhibitor for HBV AB - 101 is highly potent and activates HBV specific immune cells from chronic HBV patients AB - 101 reinvigorates HBV - specific cHBV patient T - cells * Inactive AB - 101 PDL1 PBMCs N= cells from 9 cHBV patients *p< - 0.05 * 0 3 2 1 IFN - y
Slide 21: AB-101-001: Phase 1a/1b Clinical Trial
© 2024 Arbutus Biopharma, Inc. 21 Part 1: SAD (n=8/cohort – 6:2) 1C: Dose 3 1B: Dose 2 1A: Dose 1 Part 2: MAD (n=10/cohort – 8:2) 2A: Dose ≤ dose tested in Part 1; interval TBD 2B: Dose/interval TBD 3A: Dose ≤ dose tested in Part 2; interval TBD x 28d 3B: Dose/interval TBD x 28d 3C: Dose/interval TB
Slide 22: LNP Litigation: Update
LNP Litigation: Update Moderna - Trial date April 21, 2025* • Fact discovery on - going • Markman Hearing occurred February 8, 2024 – judge heard arguments on claim construction. – Court provided ruling on April 3 and agreed with Arbutus’s position on the majority of the claims • Next Steps – Expert
Slide 23: 2024 Key Milestones
2024 Key Milestones *Consists of cash, cash equivalents and marketable securities © 2024 Arbutus Biopharma, Inc. 23 Anticipated Timing 2024 Milestone 1H AB - 729 - 201 Phase 2a (imdusiran + IFN): End - of - treatment data 1H AB - 729 - 202 Phase 2a (imdusiran + VTP - 300): End - of - treatment data
Slide 24: Thank You
Thank You © 2024 Arbutus Biopharma, Inc.